1. Nemolizumab blocks interleukin-31 signaling.
2. Significant reduction in PP-NRS scores by week 68.
3. 93% reduction in prurigo nodules observed in treatment groups.
4. 57% of patients in the 30 mg group achieved an ISI score ≤7.
5. Quality of life improved, with 75% of patients showing a DLQI improvement.
6. Reduced reliance on topical corticosteroids.
7. Most adverse events reported were mild or moderate.

Source: BJD